Drug Trial Radar · NCT05135091
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
88
Planned (sponsor's estimate)
Start
Jun 16, 2022
Primary completion
Feb 2029
Study completion Sep 2043
Sponsor
- Lead sponsor
- Neurona TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- California Institute for Regenerative Medicine (CIRM)
- First posted
- Nov 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilateral mesial temporal lobe epilepsy (MTLE), with or without mesial temporal sclerosis (MTS), is safe (frequency of adverse events) and effective (seizure frequency). NRTX-1001 comprises human interneurons that secrete a neurotransmitter, gamma-aminobutyric acid (GABA).
Conditions
- Mesial Temporal Lobe Epilepsy
Interventions
NRTX-1001Biological
Biological: NRTX-1001 is an experimental neural cell therapy product candidate derived from an allogeneic human embryonic stem cell line. The stem cells were converted into inhibitory nerve cells that produce GABA.
NRTX-1001Biological
Biological: NRTX-1001 is an experimental neural cell therapy product candidate derived from an allogeneic human embryonic stem cell line. The stem cells were converted into inhibitory nerve cells that produce GABA.
Sham ComparatorProcedure
Sham Comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of serious or severe AEs (Phase 1/2)Time frame: 1 year
- Change in disabling seizure frequency (Phase 3)Time frame: 4-6 months after surgery
Locations
36 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama · Recruiting
Mayo Clinic Arizona Epilepsy Center
Phoenix, Arizona · Recruiting
Banner-University of Arizona Medical Center Tucson Comprehensive Epilepsy Program
Tucson, Arizona · Recruiting
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Recruiting
University of Southern California Keck Hospital
Los Angeles, California · Recruiting
University of California Los Angeles
Los Angeles, California · Recruiting
UC Irvine Medical Center
Orange, California · Recruiting
Stanford University
Palo Alto, California · Recruiting
University of California Davis
Sacramento, California · Recruiting
University of California San Diego
San Diego, California · Recruiting
University of California San Francisco
San Francisco, California · Recruiting
University of Colorado Anschutz Medical Campus
Aurora, Colorado · Recruiting
George Washington University
Washington D.C., District of Columbia · Recruiting
University of Miami
Miami, Florida · Recruiting
Rush University Medical Center
Chicago, Illinois · Recruiting
University of Chicago
Chicago, Illinois · Recruiting
University of Iowa Health Care
Iowa City, Iowa · Recruiting
Ochsner Clinic Foundation
New Orleans, Louisiana · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Wayne State University/Detroit Medical Center Comprehensive Epilepsy Program
Detroit, Michigan · Recruiting
Washington University at St. Louis
St Louis, Missouri · Recruiting
Dartmouth Hitchcock Medical Center/ Department of Neurology
Lebanon, New Hampshire · Recruiting
Kaleida Health
Buffalo, New York · Recruiting
Hofstra Northwell Comprehensive Epilepsy Center
Great Neck, New York · Recruiting
NYU Langone Comprehensive Epilepsy Center
New York, New York · Recruiting
SUNY Upstate Medical University
Syracuse, New York · Recruiting
Atrium Health
Charlotte, North Carolina · Recruiting
Duke University Hospital
Durham, North Carolina · Recruiting
Atrium Wake Forest Baptist
Winston-Salem, North Carolina · Recruiting
Oregon Health and Science University
Portland, Oregon · Recruiting
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania · Recruiting
UT Southwestern Medical Center
Dallas, Texas · Recruiting
UTHealth Houston
Houston, Texas · Recruiting
University of Utah Health
Salt Lake City, Utah · Recruiting
University of Washington Regional Epilepsy Center
Seattle, Washington · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.